Exhibit 10.69

CONFIDENTIAL TREATMENT REQUESTED.
CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION.

# DEVELOPMENT SUPPLY
AGREEMENT

This Development Supply Agreement,
effective as of June 22, 2005 (the Effective Date), is made by and between
****(hereinafter ****) and Antares Pharma AG, having its principal offices
at Geweberstrasse 18, 4123 Allschwil, Switzerland (hereinafter Antares).

Antares is in the business of
marketing branded pharmaceutical products and has developed an orally disintegrating
version of **** (Product). Antares desires to have **** develop a
manufacturing and testing protocol for the Product and to manufacture quantities of the
Product for use in testing to support Antares regulatory filing. **** is engaged in
the business of commercial manufacturing, formulating and developing pharmaceutical
products in finished dosage form. The parties wish to enter into this Agreement to have
**** develop and manufacture the Product according to the terms and conditions of this
Agreement.

NOW, THEREFORE, in view of
this foregoing premise and in consideration of the foregoing premises and in consideration
of the mutual covenants set forth below, the parties agree as follows:

# 1.      DEFINITIONS

For the purposes of this Agreement,
the following terms shall have the following respective meanings:

1.1         "Development Program" shall
mean the program outlined in Appendix 1 hereto.

1.2    **** Development
Activities shall mean the activities for which **** has agreed to be responsible in
the Development Program.

1.3    Formulation shall
mean the orally disintegrating tablet formulations developed hereunder and the protocols,
batch records and all other relevant manufacturing information regarding the same.

1.4         "Product" shall mean an
orally disintegrating version of the **** oral tablet.

1.5    Specifications means
those protocols and standard operating procedures, including without limitation,
formulations, processes, quality control, compression, labeling, packaging, finishing,
storage and release requirements and/or procedures and all requisite analyses and tests
conducted in connection with any of the foregoing, in each instance conforming to cGMP,
utilized in the course of the manufacture of the Product as the same are specified in
writing by Antares and ****.

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

# 2.      CONFIDENTIALITY

The
parties acknowledge that the Confidentiality Agreement between the parties dated April 20,
2005 (the Confidentiality Agreement) shall continue to govern the
parties respective obligations to one another with regard to the confidential
information each has disclosed to the other and shall continue to disclose to the other in
connection with this Agreement. The parties respective obligations with regard to
any such confidential information shall survive the termination of this Agreement in
accordance with the terms of the Confidentiality Agreement.

# 3.      CONDUCT OF
DEVELOPMENT PROGRAM

(a)       
          **** will be responsible for performing all tasks associated with the
          development of Product that are included within the **** Development Activities.
          It is understood that Antares entire financial responsibility with respect
          to the **** Development Activities are the payments to be made by Antares to
          **** in accordance with Appendix 1. Any payment shall be made on a
          non-refundable basis unless otherwise expressly indicated.

(b)       
          In the course of performing the **** Development Activities, **** will provide
          Antares or its representative with reasonable and prompt, prior notice of all
          meetings or conferences between **** representatives (including any consultants
          and other subcontractors) and any regulatory authorities that are involved in
          review or approval of any step in the development process and will give Antares
          the right to have representatives attend all such meetings and conferences.
          Antares acknowledges that the timing of such meetings may be dictated by the
          regulatory authorities and may not be within the control of **** and that
          Antares ability to attend such meetings may be affected by the dictates of such
          authorities.

(c)       
          During the Development Program, **** shall keep Antares or its representative
          informed on a regular basis of its progress related to the development of
          Product. In a timely manner and on a regular basis during the Development
          Program (but no less often than monthly), **** shall provide Antares or its
          representative with all meeting minutes and relevant data and updated timelines
          which shall describe **** progress with respect to its development efforts under
          this Agreement.

(d)       
          Antares or its representative may, at any time Antares reasonably requests and
          with the prior approval of **** (which approval shall not be unreasonably
          withheld or delayed), visit the sites of any activities being conducted by ****
          or by any of its consultants or other subcontractors in connection with the
          Development Program or any inspections by any federal, state or local regulatory
          agency relating to the Product. **** shall cause appropriate individuals
          involved in the Development Program to be reasonably available for consultation
          with Antares.

(e)       
          It is understood that the nature, sequence and timing of the **** Development
          Activities as described herein shall not be modified absent the mutual written
          agreement of **** and Antares. However, the parties agree that the nature of the
          development process is such that modifications may be desirable or reasonably
          necessary at certain times and, therefore, the parties will follow the
          procedures set forth in this subsection (e) to implement any changes

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

deemed
          necessary. In the event that either of the parties believes that changes to the
          Development Program are required, that party shall immediately notify the other
          party in writing of the exact nature of any desired changes and the specific
          reasons therefor. If the parties are in agreement that changes to the
          Development Program should be made, then this Agreement shall be amended by the
          parties as and to the extent necessary and the appropriate party shall implement
          such changes in the Development Program. Unless and to the extent otherwise
          specifically agreed by the parties, any and all cost increases or decreases
          associated with any agreed upon changes to the Development Program shall be as
          set forth in such mutually agreed upon amendment to this Agreement.

(f)       
          **** agrees that, at all times during the performance of any of the ****
          Development Activities, it will act in accordance with cGMP and all United
          States applicable laws, rules and regulations (including, without limitation,
          any rules and regulations of the FDA). **** represents and warrants: (i) that it
          will at all times use commercially reasonable efforts in the conduct of the ****
          Development Activities, (ii) its facilities and resources are adequate to
          perform the **** Development Activities, and (iii) that the **** personnel
          assigned to perform the **** Development Activities under this Agreement have
          the requisite skills and training to carry out the **** Development Activities
          in a professional and workmanlike manner.

(g)       
          **** will use commercially reasonable efforts to complete the **** Development
          Activities within the timelines set forth herein and in Appendix 1. Antares
          acknowledges and agrees that **** will require certain information and
          reasonable cooperation from Antares in order to properly perform the ****
          Development Activities within the timelines set forth herein and in Appendix 1
          and that **** is not responsible for delays in its performance caused by
          Antares failure to provide such information and reasonable cooperation to
          **** in a timely manner.

# 4.      REGULATORY

(a)       
          It is understood that **** will provide Antares with all reasonable assistance
          with respect to all filings with the FDA including the CMC section of the ****
          describing the manufacturing process for the Product.

(b)       
          **** agrees, upon request from Antares, promptly to provide Antares with such
          information as Antares may reasonably require to complete any and all United
          States regulatory filings and submissions.

(c)       
          Subject to the limitations set forth herein and for the avoidance of doubt, it
          is understood that Antares will be the owner of the Product **** and will have
          sole and exclusive rights to market and sell the Product in the United States.
          **** shall not directly or indirectly, on its own behalf or on behalf of others
          engage in the development, manufacturing, and/or supply of a solid, orally
          administered ODT (orally disintegrating tablet) **** dosage form during the term
          of this Agreement and for a period of one year thereafter provided, however,
          that if Antares engages **** to provide **** Development Activities that run for
          a period of at least two years under this Agreement, the latter period shall be
          extended to run for a period of two years; provided, further however, in the
          event the agreement is terminated due to a breach of any of

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

Antares
          obligations hereunder, **** shall not be bound by the foregoing restriction,
          which shall be null and void.

# 5.      MANUFACTURE

At such time as Antares begins
commercialization of the Product, but subject to Antares offering **** the first
opportunity to enter into a mutually agreeable Manufacturing Agreement, **** will
manufacture the Product in accordance with the terms and conditions of the Manufacturing
Agreement.

6.     OWNERSHIP OF MATERIALS AND INFORMATION

(a)    
          All data, information, reports and any and all related documentation, which are
          developed, generated or derived, directly or indirectly, by **** (or by any
          subcontractor or agent of ****) for Antares during the course of this Agreement
          (the Data), and all inventions, discoveries, formulae (including the
          Formulation), procedures, any other intellectual property, and any improvements
          thereto, whether patentable or not, which result or evolve directly, during the
          course of this Agreement or as a result of the services performed hereunder by
          **** (or by any subcontractor or agent or ****) (together with any Data relating
          thereto, the Inventions), shall be and remain the sole and exclusive
          property of Antares if related to the Product; provided, however, any Inventions
          made, developed or discovered solely by **** (or by any subcontractor or agent
          of ****) that constitute an invention, improvement or other intellectual
          property relating to drug delivery technology, formulation (exclusive of the
          Product itself), analysis or manufacturing process of pharmaceutical products
          (together with any Data relating thereto, **** Inventions), shall be
          and remain the property of ****, and **** hereby grants to Antares a
          royalty-free, exclusive worldwide license (including the right to sublicense) to
          develop, use, manufacture and sell such **** Inventions in connection with the
          development, use, manufacture, importation, and sale of the Product. Except as
          specifically set forth herein, neither **** nor its employees or agents shall
          have or acquire any right, title or interest in Inventions. **** shall promptly
          disclose in writing to Antares any Inventions. If related to the Product and to
          the extent not **** Inventions, **** shall assign any and all rights in any
          Inventions to Antares and shall assist Antares, at no cost to ****, in
          perfecting its rights in such Inventions.

(b)    
          **** agrees that it will not abandon the prosecution of any patent applications
          directed to the **** Inventions nor will it fail to make any payment or fail to
          take any other action necessary to maintain its rights to an issued patent or
          any other item included in the **** Inventions without providing Antares
          reasonable notice of its intention to abandon or not maintain such patent or
          patent application and giving Antares the opportunity to take such action at
          Antares expense whereupon **** shall transfer title to the patent or
          application to Antares. **** also agrees that it will at all times take all
          commercially reasonably available steps to prevent the disclosure,
          misappropriation or misuse of any trade secrets and other non-patented
          technology included in the **** Inventions. **** and Antares shall each promptly
          notify the other in writing of any alleged or threatened infringement of patents
          or patent applications included in the **** Inventions by a **** product of
          which they become aware. If, in the reasonable judgment of Antares, any such
          actual or alleged infringement poses a material threat to the development,

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

commercial viability or success of the Product, Antares shall have the right to
          prosecute any such infringement using counsel of its selection and **** shall
          provide Antares with its full support, at Antares cost and expense, including
          joining in such an action as a co-party plaintiff if required. The cost of such
          infringement prosecution will be borne by Antares. Any recoveries or damages
          derived from such action shall also be for the account of Antares, to the extent
          relating to the Product.

7.     
          TERMINATION

(a)       
          Antares, but not ****, may terminate this Agreement at any time and for any
          reason at the sole discretion of Antares upon thirty (30) days advance written
          notice to ****. Upon such termination, Antares shall pay all costs incurred by
          **** for work performed prior to the effective date of termination, provided
          **** provides written evidence that such costs have been incurred and such work
          performed, and for non-cancelable costs incurred by **** and costs associated
          with concluding any in-process testing and provision of final reports, in
          accordance herewith through the effective date of such termination. Either party
          may terminate this Agreement if the other party is in default of any of its
          material obligations set forth herein, and such breach is not cured within sixty
          (60) days, which time period shall be reduced to twenty-five (25) days for any
          default of any monetary obligation, after the breaching partys receipt of
          a written notice from the non-breaching party that describes such breach in
          reasonable detail. Unpaid balances shall bear interest at a rate of 12% per
          annum unless determined not to be properly payable.

(b)       
          The expiration or termination of this Agreement for any reason shall not relieve
          the parties of any obligation that accrued prior to such expiration or
          termination.

# 8.      NOTIFICATION OF
SUB-CONTRACT LABS

Insofar
as **** anticipates using contract laboratories for some of the activities described in
this Agreement, **** shall notify Antares when use of such contract laboratories becomes
necessary and subject to Antares consent, which shall not be unreasonably withheld,
**** may employ such laboratories. **** shall be responsible for assuring that any
contract lab used complies with Good Laboratory Practices.

# 9.      WARRANTIES

(a)       
          **** represents and warrants to Antares that it has the full power and authority
          to enter into this Agreement and to grant to Antares the rights granted
          hereunder and that this Agreement is enforceable against **** in accordance with
          its terms, and that the execution and performance of this Agreement by **** is
          not subject to any restriction of any kind and will not violate any laws,
          decrees, agreements or the corporate governance and organizational documents of
          ****, which restriction or violation might have any material adverse effect on
          the exercise or scope of the rights of Antares hereunder.

(b)       
          **** warrants and covenants that it will perform all of its obligations under
          this

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

Agreement in accordance with all applicable United States laws and
          regulations. Without limiting the generality of the foregoing, **** warrants and
          covenants that all CTM will meet the Specifications and will have been produced
          in compliance with cGMPs and that upon delivery any Product supplied hereunder
          will meet the applicable Specifications and otherwise be as warranted herein and
          will not be adulterated or misbranded within the meaning of the Food Drug and
          Cosmetic Act. **** further represents and warrants that neither it nor any of
          its officers or employees nor anyone providing services to it in conjunction
          with this Agreement has been debarred under 21 U.S.C.§ 335(a) or (b).

(c)       
          **** further represents and warrants: (i) to its knowledge and belief, its
          activities under this Agreement and the manufacture, use, sale and importation
          of the Product will not infringe the intellectual property rights of any party,
          and (ii) with regard to its activities under this Agreement, it has not received
          any notice of infringement or potential infringement from any party.

(d)       
          EXCEPT AS SPECIFICALLY SET FORTH IN THIS AGREEMENT, **** MAKES NO
          EXPRESS OR IMPLIED WARRANTIES OR COVENANTS, STATUTORY OR OTHERWISE, CONCERNING
          THE DELIVERABLES. WITHOUT LIMITING THE FOREGOING,**** MAKES NO IMPLIED
          WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE REGARDING THE
          DELIVERABLES.Without limiting the foregoing, in no event shall **** shall
          be responsible for the stability of the Product manufactured in accordance with
          the Specifications. For the avoidance of doubt, **** will be responsible for
          testing the stability of the Product.

(e)       
          Antares represents and warrants to **** that, except to the extent that any of
          the following are the obligations(s) of ****: (a) Antares shall comply with
          applicable laws and regulations and Antares shall keep **** fully informed of
          any development that would affect **** manufacturing of the Product hereunder;
          and (b) any active pharmaceutical ingredient furnished by Antares shall meet
          required Specifications, be suitable for use in the further processing of the
          Product, and shall not contain any viruses or other deleterious substances which
          could contaminate the processing operations of **** or any latent defects.
          Antares further represents and warrants to **** that it has the full power and
          authority to enter into this Agreement and to grant to **** the rights granted
          hereunder and that this Agreement is enforceable against Antares in accordance
          with its terms, and that the execution and performance of this Agreement by
          Antares is not subject to any restriction of any kind and will not violate any
          laws, decrees, agreements or the corporate governance and organizational
          documents of Antares, which restriction or violation might have any material
          adverse effect on the exercise or scope of the rights of **** hereunder.

(f)       
          Each Party represents and warrants that neither it nor any persons supervising,
          administering or performing any obligations pursuant to this Agreement has ever
          been, is currently, or at any time during the term of this Agreement shall be:
          (i) excluded, barred from participation in, or sanctioned by any state or
          federal health care program, including without limitation Medicare or Medicaid;
          (ii) the recipient of a criminal conviction related to any such health care
          program; or (iii) under investigation by the FDA for debarment action or
          debarred

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

pursuant to the Generic Drug Enforcement Act of 1992, as amended (21
          U.S.C. §301 et seq.). No party shall use the services of any person who has
          been disbarred under the Generic Drug Enforcement Act of 1992, as amended, in
          any capacity, in connection with any of the Work provided hereunder. It is
          understood and agreed that this Agreement imposes a continuing obligation upon
          each party to notify the other of any change of circumstances with regard to
          this Section.

# 10.     ACCEPTANCE OF
SHIPMENTS; NON-CONFORMANCE

(a)       
          **** will manufacture, package and test Product according to the agreed upon
          procedures and Specifications. **** will notify and obtain written approval from
          Antares of any and all proposed changes in its manufacturing, packaging or
          testing procedures relating to Product. All references to Antares in this
          Article 10 shall include its agent ****.

(b)    
          For each shipment hereunder, **** shall provide a Certificate of Analysis and
          within thirty (30) days following delivery to Antares, Antares shall have the
          right to give **** notice of rejection of any shipment that, in whole or part,
          fails to meet Specifications or which otherwise breaches **** warranties set
          forth herein. Antares shall at all times supply **** with any evidence it has
          that relates to whether any Product delivered to Antares by **** is
          non-conforming as contemplated hereunder. Failure by Antares to give notice of
          rejection within 30 days of the date of its receipt shall constitute acceptance
          by it of the shipment to which the notice of rejection would have otherwise
          applied. In the event of any disagreement between **** and Antares relating to
          Product conformance with Specifications or **** warranties set forth herein, the
          parties will use best good faith efforts to reach an amicable resolution of such
          disagreement. In the event that resolution cannot be reached, a mutually agreed
          upon, neutral, independent third party laboratory shall be brought in to resolve
          the disagreement upon the request of either party. The results of the
          independent laboratory shall be binding on the parties and non-appealable, and
          the cost of such independent laboratory shall be borne by the party hereunder
          determined by the independent laboratory to be the non-prevailing party in such
          disagreement. For any Product properly rejected pursuant to this Section, such
          Product shall be returned by Antares to **** at **** expense and shall be
          replaced by **** at no extra charge to Antares, subject to the Antares
          provision to **** of Antares Materials, including any active pharmaceutical
          ingredient (API). In the event **** cannot replace such defective
          Product, it shall refund to Antares the amount paid therefor. Notwithstanding
          anything to the contrary contained herein, **** shall not be responsible for any
          non-conforming Product except to the extent of its negligence or willful
          misconduct in the performance of its obligations hereunder.

(c)       
          **** will deliver or arrange for the delivery of Product to a destination point
          designated by Antares, at the expense of Antares, Ex Works (Incoterms 2000),
          **** loading dock, ****. Title to Product will pass to Antares upon leaving ****
          loading dock, whereupon Antares will assume all risk of loss or damage.

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

# 11.     INDEMNIFICATION AND
INSURANCE

(a)       
          Antares agrees to indemnify, defend and hold harmless ****, its stockholders,
          directors, officers, employees and agents from and against any and all claims,
          losses, liabilities, lawsuits, proceedings, costs and expenses, including
          without limitation, reasonable attorneys fees and the cost of recalls (a
          Claim) arising out of or in connection with: (i) injuries and/or
          death to humans resulting from the use of any materials provided to **** by
          Antares (including all manufactured products or materials resulting from the
          provision of **** services hereunder), including, without limitation, claims
          based on negligence, warranty, strict liability or any other theory of product
          liability or a violation of applicable laws or regulations, except to the extent
          that such injuries or violations are the result of **** negligence or willful
          misconduct in performing the services hereunder or breach of any covenant or
          agreement hereunder, (ii) negligence or willful misconduct in advertising,
          labeling, or improper handling and storage by any person other than ****, (iii)
          any specifications provided by Antares that are incorrect or do not meet FDA
          approved specifications, or other instructions given by Antares in connection
          with any materials provided to **** by Antares or **** services provided
          hereunder, (iv) any misrepresentation by Antares or breach by Antares of any
          covenant or agreement hereunder or (v) patent infringement relating to any
          materials provided to **** by Antares or **** services provided hereunder;
          except to the extent with regard to clauses (i) through (v) above that such
          Claim arises from an act or occurrence for which **** has indemnified Antares
          hereunder.

(b)       
          **** shall indemnify and hold harmless Antares and Antares affiliates, and
          its and their stockholders, directors, officers, employees and agents from and
          against any and all claims, losses, liabilities, lawsuits, proceedings, costs
          and expenses, including without limitation, reasonable attorneys fees and
          the cost of recalls arising out of or in connection with: (i) any negligence or
          willful misconduct of **** in performing the services hereunder, (ii) any
          misrepresentation by **** or breach by **** of any covenant or agreement
          hereunder, or (iii) any claim asserted by a third party that **** in performing
          the services hereunder has infringed or misappropriated any proprietary or
          confidential information or intellectual property rights of such third party,
          except as relate to any materials, specifications or instructions provided to
          **** by Antares or on behalf of Antares; or (iv) any failure of Product
          delivered by **** to meet the Specifications except as and to the extent such
          failure is related to stability of the Product or any defects in the API not
          attributable to negligent acts or omissions to act by ****; except to the extent
          with regard to clauses (i) though (iv) above that such Claim arises from an act
          or occurrence for which Antares has indemnified **** hereunder.

(c)       
          IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR INDIRECT DAMAGES OR
          CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION, LOST PROFITS OR REVENUES,
          EXCEPT TO THE EXTENT THAT THEY ARE RELATED TO A CLAIM OF A THIRD PARTY WHICH IS
          NOT IN PRIVITY WITH EITHER PARTY THAT IS THE SUBJECT OF ONE OF THE ABOVE
          INDEMNIFICATIONS.

(d)       
          Procedure. Unless and to the extent otherwise specifically provided
          herein, a party or any of its Affiliates (the Indemnitee) that
          intends to claim indemnification under this

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

Article shall promptly notify the
          other party (the Indemnitor) of any loss, claim, damage, or
          liability arising out of any third party claim or action in respect of which the
          Indemnitee intends to claim such indemnification, and the Indemnitor shall
          assume the defense thereof with counsel of its own choosing; provided, however,
          that an Indemnitee shall have the right to retain its own counsel, with the fees
          and expenses to be paid by the Indemnitor, if representation of such Indemnitee
          by the counsel retained by the Indemnitor, in the opinion of an independent
          counsel chosen by both parties, would be inappropriate due to actual or
          potential differing interests between such Indemnitee and any other party
          represented by such counsel in such proceedings. An Indemnitee shall not be
          entitled to indemnification under this Article if any settlement or compromise
          of a third party claim is effected by the Indemnitee without the consent of the
          Indemnitor.

(e)       
          **** represents and warrants that it has obtained and shall at all times during
          the term of this Agreement and for at least 3 years following its termination
          maintain at its own cost and expense, in respect to its performance hereunder:
          (a) physical damage property insurance on all of the Product **** at all times
          it is in **** possession and before delivery to the carrier on behalf of
          Antares. Such insurance shall be in the amount of the full replacement value of
          all such property and Product; (b) workers compensation insurance in
          accordance with the statutory requirements of ****; and (c) product liability
          insurance and general liability insurance, including contractual liability
          insurance, in each case, with a minimum of Five Million Dollars ($5,000,000) per
          occurrence which includes Antares as an additional insured.

(f)       
          Antares represents and warrants that it has obtained and shall at all times
          during the term of this Agreement and for at least 3 years thereafter maintain
          at its own cost and expense product liability insurance with respect to the
          Product with minimum coverage of Five Million Dollars ($5,000,000) per
          occurrence and which includes **** as an additional insured.

# 12.     FORCE MAJEURE

Failure
of any party to perform its obligations under this Agreement (except the obligation to
make payments) shall not subject such party to any liability or place it in breach of any
term or condition of this Agreement to the other party if such failure is caused by any
cause beyond the reasonable control of such non-performing party, including, without
limitation, acts of God, fire, explosion, flood, drought, war, riot, sabotage, embargo,
interruption of or delay in transportation, a national health emergency or compliance with
any order or regulation of any government entity acting with color of right.

# 13.     GOVERNING LAW

This
Agreement shall be governed by and construed in accordance with the laws of the Delaware
(exclusive of its conflicts of laws provisions).

# 14.     DISPUTES; ARBITRATION

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

(a)       
          Except as provided in clause (c) below or in Section 6 with respect to disputes
          regarding non-conforming shipments, all disputes, controversies or claims
          arising out of or relating to the operation or interpretation of this Agreement
          shall be resolved by arbitration before one arbitrator in accordance with the
          Commercial Rules of the American Arbitration Association. The arbitrator shall
          be jointly selected by the parties. Any award rendered by the arbitrator shall
          be final and binding upon the parties and judgment upon any such award may be
          entered in any court having jurisdiction thereof. Arbitration shall be conducted
          in Delaware. The parties shall share the costs and expenses of the arbitrator,
          and each party shall bear its cost of the arbitration including its own attorney
          fees.

(b)       
          Notwithstanding anything to the contrary contained in this Section, in the event
          of any breach or threatened breach of this Agreement by either party that the
          other party believes will cause irreparable harm and damage to it, such party
          shall be entitled to an injunction, restraining order restraining such breach or
          threatened breach by the other party and all other remedies which shall be
          available to it at law or in equity and the parties irrevocably submit to the
          jurisdiction of any state or federal court sitting in the state of Delaware over
          any such suit, action or proceeding. The parties irrevocably waive, to the
          fullest extent permitted by law, any objection that it may now or hereafter have
          to the laying of the venue of any such suit, action or proceeding brought in any
          such court and any claim that any such suit, action or proceeding brought in any
          such court has been brought in an inconvenient forum.

# 15.     NON-SOLICITATION AND
HIRING

During
the term of this Agreement and for a period of two (2) years thereafter, regardless of the
reason for such termination, neither party will, directly or indirectly, without the prior
written consent of the other party, solicit or hire, as an employee or independent
contractor, any person who is, or was at any time, employed by or under contract with the
other party, unless at the time of the solicitation or hiring, at least one (1) year shall
have elapsed since the person was last employed by or under contract with the other party.

# 16.     MISCELLANEOUS

(a)       
          Waiver; Integration; Modification. The waiver of the breach of any term
          or provision of this Agreement shall not operate as or be construed to be a
          waiver of any other or subsequent breach of this Agreement. This Agreement sets
          forth the entire agreement between the parties with respect to the subject
          matter of this Agreement and merges and supersedes all prior discussions,
          agreements and understandings of every nature between them. No modification or
          amendment to this Agreement or any other agreement with respect to the subject
          matter of this Agreement shall be effective unless stated in writing and signed
          by the parties.

(b)       
          Construction. Whenever the context may require, the singular form of
          names and pronouns shall include the plural and vice-versa. The section and
          subsection headings are included solely for the convenience of the parties and
          shall not be used in the interpretation of this Agreement. No rule of
          construction shall apply to this Agreement that construes any language, whether
          ambiguous, unclear or otherwise, in favor of or against any party based on the
          party that drafted such language.

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

(c)       
          Counterparts. This Agreement may be executed in any number of
          counterparts, and each such counterpart shall be deemed to be an original
          instrument, but all such counterparts together shall constitute but one
          agreement.

(d)       
          Survival. No termination or expiration of this Agreement shall relieve
          the parties hereto of any obligation hereunder which by their terms are intended
          to or may survive the termination or expiration of this Agreement, including but
          not by way of limitation, the provisions of Sections 2, 4(c), 6, 9, 11, 13, 14,
          15, and 16.

(e)       
          Relationship Between Parties. **** relationship to Antares shall be that
          of an independent contractor. No persons engaged by **** shall be considered
          under the provisions of this Agreement or otherwise as an employee of Antares.
          Nothing contained in this Agreement shall create or imply the creation of a
          partnership between Antares and **** and neither party shall have any authority
          (actual or apparent) to bind the other. Antares acknowledges and agrees that
          **** (****) is the agent of Antares, **** has the full power to bind Antares
          with respect to any action required of Antares hereunder and **** shall be
          entitled to rely on all actions taken by **** purported to be on behalf of
          Antares.

(f)       
          Assignment. Except as provided in Section 8 above or in connection with a
          sale of substantially all of **** assets, **** shall not assign its rights or
          obligations under this agreement, and any purported assignment shall be null and
          void and without force or effect.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives.

|****                                                 |  | Antares Pharma AG                                                               | 
|---------------------------------------------------- |  | ------------------------------------------------------------------------------- | 
|/s/ ****
****                 
President and CEO/SVP |  | /s/ Darrio Carrara, PhD
Darrio Carrara, PhD
Managing Director, Swiss Operations | 
|6/23/2005
Date                                       |  | June 24, 2005
Date                                                              | 
|                                                     |  | Billing Contact:                                                                | 
|                                                     |  | Address:                                                                        | 
|                                                     |  | City, State, Zip:                                                               | 

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

| |  | Phone:         | 
| |  | -------------- | 
| |  | Fax:           | 
| |  | Email Address: | 
| |  | PO Number:     | 

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

# APPENDIX 1

# DEVELOPMENT PROGRAM

# Development and
Manufacture of **** Tablets



|****Contact: Address: | **** Vice President of CMC Services****
|--------------------- | ---------------------------------------

|Phone: Fax:Email: | ************
|----------------- | ------------

|Antares Pharma Contact:Phone:Email: | Holger Kraus Project Manager  Antares Pharma AG
Gewerbestrasse 18CH-4123 Allschwil Switzerland+41 (61) 486 41 45hkraus@antarespharma.ch
|----------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------

|****Contacts: Corporate Phone:Corporate Fax: | ****************
************
|-------------------------------------------- | -----------------------------

|**** Phone:**** Fax:Email: | ************
|-------------------------- | ------------

Project number: ****

The proposal is split into three
sections: (A) Project Definition
and Scope(B) Costs(C) Legal and Signatures

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

# (A)     Project Definition
and Scope

Antares Pharma AG is planning to file
an **** tablet product with the objective being to develop an orally disintegrating
version of the **** oral tablet. Antares requires **** to develop the orally
disintegrating tablet formulation version of the ****. **** will manufacture one (1) ****
of approximately **** tablets for the **** strength and manufacture one (1) **** of
approximately **** tablets for the **** strength if the filing is an ****.

Antares Pharma AG
(Antares) has contracted with **** (**** ) to oversee the pharmaceutical
development program.

Product is defined as
**** in Section 1.4.

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

**** tablets is a **** drug indicated
for relief of the signs and symptoms of ****. **** was developed by ****.

****, an **** derivative, is a member of
the **** and is structurally related to ****. Each **** tablet contains **** for oral
administration. **** is chemically designated as ****. The molecular weight is ****.

**** is a **** solid, **** in water,
with higher solubility observed in ****. It is very slight soluble in ****. **** has an
apparent partition coefficient = ****. **** has pKa ****.

The inactive ingredients in ****
tablets include ****.

# Antares will supply:

| | API
 (****) with Certificate of Analysis (C of A) and Material Safety Data Sheet (MSDS)Reference standard and impurities
Innovator Product  up to 3 lotsTechnical
data package including methods, if any and formulationAnalytical methods for API with
validation package, if available
|----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**** will order and invoice to
Antares:

| | Excipients with C of A and MSDSPackaging components with Certificate of Compliance (C of C) and MSDS
Analytical columnsTooling per **** specifications - up to 40 stations per setBlister tooling
|----- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

# **** Services:

|1. | Materials:**** will order sufficient materials for all activities in
          this proposal.**** will use stock excipients where possible and
          will bill for materials and testing at the completion of this contract.
|-- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 1.1 | ****
 **** will receive on C of A and perform full release testing.  **** will perform I.D.
testing on any non GMP                   batches of API received.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 1.2 | Excipients  **** will
receive on C of A and perform USP full release testing.
| | --- | ------------------------------------------------------------------------------

| | 1.3 | Packaging components  ****
will receive on C of C and perform USP full release testing.
| | --- | ----------------------------------------------------------------------------------------

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

|2. | Formulation
Development
|-- | -----------------------

| | 2.1 | **** will develop a discriminating dissolution method and will perform dissolution testing
of innovator product  up to three (3) lots to use for comparative dissolution
screening.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 2.2 | ****
will provide the formulation for each strength, which is a direct compression.
| | --- | -----------------------------------------------------------------------------------

| | 2.3 | **** will prepare a development
protocol and have signed by **** prior to initiating development activities.
| | --- | ------------------------------------------------------------------------------------------------------------

| | 2.4 | Manufacture
of two (2) prototypes- one (1) x ****  and one (1) x **** at approximately **** tablets
in scale.  ****                   will test for the following:
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 2.4.1 | Dissolution Profile
if not provided by Antares
| | ----- | ----------------------------------------------

| | 2.4.2 | Physical Appearance
| | ----- | -------------------

| | 2.4.3 | Assay and Related
Substances
| | ----- | ----------------------------

| | 2.4.4 | Content Uniformity
| | ----- | ------------------

| | 2.4.5 | Disintegration
| | ----- | --------------

| | 2.4.6 | Moisture by KF
| | ----- | --------------

| | 2.4.7 | Blend Uniformity
| | ----- | ----------------

| | 2.4.8 | Bulk / Tap Density
| | ----- | ------------------

| | 2.4.9 | Tablet Compression Characteristics (= Tablet properties? See §2.4.11 here below)
| | ----- | --------------------------------------------------------------------------------

| | 2.4.10 | Taste Masking Evaluation to be performed by Antares  development samples will be
sent to Antares. Results will be provided to **** within one (1) week of receipt of
samples in order to maintain project time lines.
| | ------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 2.4.11 | Tablet properties (weight variation, hardness, thickness, friability and disintegration)
| | ------ | ----------------------------------------------------------------------------------------

| | 2.5 | **** will perform tablet compression studies on the two (2) tablet strengths.
| | --- | -----------------------------------------------------------------------------

| | 2.6 | The **** prototype will be placed on accelerated stability in two (2) package
configurations (aclar blisters and foil/foil blisters) at 40°C/75% RH and will be
tested at 1, 2 and 3 months for dissolution and assay and related substances, moisture,
appearance and tablets properties. (Total two (2) batches on stability  1 prototype
in 2 package configurations)
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Condition  | Initial | 1 Month | 2 Months | 3 Months
|---------- | ------- | ------- | -------- | --------
|40°C/75%RH | X       | X       | X        | X       
|25°C/60%RH |         | 0       | 0        | 0       

| | 0-Optional
| | ----------

Decision Point 1:      ****,
Antares and**** will review the one (1) month stability data to

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

move forward with
the manufacture of the feasibility batch.

Decision Point 2:      ****,
Antares and**** will review the two (2) month stability data to order the blister
tooling (aclar with foil backing or foil/foil).

NOTE:**** will package in
blister cards with in house tooling for the development batches in aclar and foil/foil .
Tooling will have to be ordered immediately once final formulation and tablet weight,
thickness confirmed so prototypes can be sent to blister tooling manufacturer.

|3. | Manufacture of the Feasibility/Scale-Up Batches of the**** strengths
          (Batch sizes will be approximately **** tablets per batch)
|-- | -----------------------------------------------------------------------------------------------------------------------------------------

| | 3.1 | All
materials used for the manufacture of the feasibility batches will be released by I.D.
unless otherwise                   specified by ****.  See Materials: Sections 1.1 & 1.2
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 3.2 | **** will prepare
feasibility batch records and document all activities in the project notebook.
| | --- | ------------------------------------------------------------------------------------------------

| | 3.3 | Operators will wear respirators.
| | --- | --------------------------------

| | 3.4 | **** will use the following equipment train:
| | --- | --------------------------------------------

| |  | V-Blender
| | - | ---------

| |  | Tablet Press
| | - | ------------

| | 3.5 | **** will perform the following in-process testing on the feasibility batches (to be confirmed  by  ****):
| | --- | ----------------------------------------------------------------------------------------------------------

| |  | Blend Uniformity Assay
| | - | ----------------------

| |  | Bulk and Tap Density
| | - | --------------------

| |  | Sieve Analysis
| | - | --------------

| |  | Tablet properties (weight variation,
hardness, thickness, friability and disintegration)
| | - | ----------------------------------------------------------------------------------------

| | 3.6 | **** will perform the following finished product testing on the feasibility batches:
| | --- | ------------------------------------------------------------------------------------

| |  | Appearance
| | - | ----------

| |  | Moisture
| | - | --------

| |  | Content uniformity of dosage units
| | - | ----------------------------------

| |  | Dissolution profile
| | - | -------------------

| |  | HPLC assay and related substances
| | - | ---------------------------------

| |  | Disintegration
| | - | --------------

|4. | Manufacture of the one (1) **** and the one (1) **** if**** filing
           Batch sizes will yield approximately **** tablets per batch
|-- | ------------------------------------------------------------------------------------------------------------------------------------------

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

| | 4.1 | All
materials used for the manufacture of the Batches will be fully released by **** unless
otherwise specified by ****.
          See Materials: Sections 1.1 & 1.2
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 4.2 | **** will prepare Master Batch Records that will be approved by **** at least one (1) week
prior to manufacture of the Batches.
| | --- | -------------------------------------------------------------------------------------------------------------------------------

| | 4.3 | The
Batches will be manufactured under cGMP conditions as directed in the Master Batch
Records.
| | --- | -----------------------------------------------------------------------------------------------

| | 4.4 | Operators
will wear respirators.
| | --- | --------------------------------

| | 4.5 | ****
will remove periodic samples per the agreed sampling protocols.
| | --- | --------------------------------------------------------------------

| | 4.6 | Based
on the experience gained from Formulation Development and Feasibility Batches (See
Sections 2 and 3), ****  will manufacture one (1) **** (**** strength) and one (1)
**** (**** strength) of **** tablets if **** filing. The batches will yield approximately
**** tablets per batch.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 4.7 | ****
will use the following equipment train:
| | --- | --------------------------------------------

| |  | V-Blender
| | - | ---------

| |  | Tablet
Press
| | - | ------------

| | 4.8 | ****
will perform the following in-process testing on the batches (to be confirmed by ****):
| | --- | --------------------------------------------------------------------------------------------

| |  | Blend Uniformity Assay
| | - | ----------------------

| |  | Bulk and Tap Density
| | - | --------------------

| |  | Sieve Analysis
| | - | --------------

| |  | Tablet properties (weight variation, thickness, hardness, friability and disintegration)
| | - | ----------------------------------------------------------------------------------------

| | 4.9 | **** will perform the following finished product testing on the batches or as per mutually
agreed upon by **** and **** (should meet Master Specifications):
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | Appearance
| | - | ----------

| |  | Moisture
| | - | --------

| |  | Content uniformity
| | - | ------------------

| |  | Dissolution
profile
| | - | -------------------

| |  | HPLC assay and related substances
| | - | ---------------------------------

| |  | Disintegration
| | - | --------------

| | 4.10 | **** will store, monitor and
test the stability of the batches per the **** approved protocols (See Section 6).
| | ---- | ---------------------------------------------------------------------------------------------------------------

|5. | Packaging and Labeling
of Batches
|-- | ---------------------------------

| | 5.1 | Materials: See
Section 1.3.
| | --- | ---------------------------

| | 5.2 | Packaging and labeling protocols will be prepared by **** one (1) week prior to the manufacture of the batches.
| | --- | ---------------------------------------------------------------------------------------------------------------

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

| | 5.3 | The batches will be packaged per **** approved packaging protocols.
| | --- | -------------------------------------------------------------------

| | 5.3.1 | Blisters of 10 (ten) tablets with three (3) cards per carton (total 30 tablets)
| | ----- | -------------------------------------------------------------------------------

| | 5.4 | The batches will be labeled with ink-jetted lot numbers per **** approved labeling protocols.
| | --- | ---------------------------------------------------------------------------------------------

| | 5.5 | Any remaining tablets will be stored in bulk.
| | --- | ---------------------------------------------

|6. | Stability of Batches
and ****
|-- | -----------------------------

| | 6.1 | **** will monitor and test, using **** approved stability protocol, the stability of ****
and finished product; the stability program is to be initiated as soon as the tablets are
manufactured and packaged.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 6.2 | Stability of the
Packaged Product:
| | --- | ----------------------------------

| | 6.2.1 | The packaged batches of **** tablets (**** strengths) will be set down on stability in
blisters. Number of batches will be confirmed once **** has decision from FDA on filing
type (e.g. ****). There will be two (2) batches set on stability.
| | ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 6.2.2 | Stability protocols will be developed per ICH guidelines. The stability protocols will
include a **** long term stability at 25°C+/-2°C /60% +/-5% RH
(25°C/60% RH) and a **** accelerated stability at 40°C+/-2°C /75%
+/-5% RH (40°C/75% RH). **** may elect to include a 12 month intermediate stability
at 30°C+/-2°C /65% +/-5% RH (30°C/65% RH) in the protocol. Sufficient
samples will be placed on stability to meet the stability protocol requirements.
| | ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 6.2.3 | The packaged product on stability will be tested at **** months at 40°C/75% RH and
**** months at 25°C/60% RH. Samples stored at 30°C/65% RH will be tested if
significant change occurs at the accelerated conditions or by **** request.
| | ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Condition                                                                                                    | Initial
** | **** | **** | **** | **** | **** | **** | **** | **** | ****
|------------------------------------------------------------------------------------------------------------ | ---------- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ----
|25°C/60%RH                                                                                                   |            | 0    | 0    | X    | X    | X    | X    | X    | X    | X   
|40°C/75%RH                                                                                                   | X          | X    | X    | X    | 0    |      |      |      |      |     
|30°C/65%RH*                                                                                                  |            |      |      | 0    | 0    | 0    | 0    |      |      |     
|* Optional, will be initiated subsequent to failure at 40°C/75% RH or at **** request                       
|**Release data will be used at Time 0 (initial) if stability is initiated within one (1) month of production

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

| | 6.3 | ****:
| | --- | -----

| | 6.4 | Stability Tests:
| | --- | ----------------

| | 6.4.1 | The following tests will be performed on the batches if not specified in the approved protocol otherwise: (**** will
                           confirm testing)
| | ----- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | Moisture (KF)
| | - | -------------

| |  | Physical
Appearance
| | - | -------------------

| |  | Assay and related substances
| | - | ----------------------------

| |  | Dissolution
| | - | -----------

| |  | Disintegration
| | - | --------------

| |  | Leak Testing
| | - | ------------

| |  | Moisture permeation
| | - | -------------------

| |  | Container/Closure
| | - | -----------------

| |  | Tablet properties (weight variation, hardness, thickness, friability and disintegration)
| | - | ----------------------------------------------------------------------------------------

| | 6.5 | General Stability
Support:
| | --- | --------------------------

| | 6.5.1 | **** will prepare stability protocols and **** and Antares will review and approve the
stability protocols one (1) week prior to initiation of stability study.
| | ----- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 6.5.2 | **** will complete stability testing within thirty (30) calendar days from the scheduled
pull date. **** and Antares will be notified in writing of any testing that will not be
completed in this time frame.
| | ----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 6.5.3 | **** will provide to **** and Antares test results upon completion at each stability time
point and not later than forty-five (45) calendar days from the scheduled pull date.
| | ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 6.5.4 | **** and Antares will be notified of any Out-of-Specification (OOS) Result within three
(3) days of completion of Phase I Investigation when the OOS Result was confirmed.
Investigations will be billed to Antares based upon work scope.
| | ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | ****
will provide to **** and Antares an updated stability summary table after each stability
time point.
| | ---------------------------------------------------------------------------------------------------------

|7 | Analytical Support
|- | ------------------

| | 7.1 | **** will develop and validate the following analytical methods:
| | --- | ----------------------------------------------------------------

| |  | Cleaning
| | - | --------

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

| |  | Assay and related substances for drug product
| | - | ---------------------------------------------

| |  | Dissolution for drug product
| | - | ----------------------------

| | 7.2 | **** will perform validation of the following methods:
| | --- | ------------------------------------------------------

| |  | HPLC Assay and Related Substances for API
| | - | -----------------------------------------

| |  | Residual Solvents for API
| | - | -------------------------

| | 7.3 | Innovator (Reference) Product Testing concurrent with the ****
| | --- | --------------------------------------------------------------

| |  | Dissolution Profile at n=12
| | - | ---------------------------

| |  | Content Uniformity at n=30
| | - | --------------------------

| |  | Assay and Related Substances
| | - | ----------------------------

Note:  Any
additional analytical methods will be covered under a separate change order.

|8 | Filing Documentation
|- | --------------------

| | 8.1 | Master Specifications
| | --- | ---------------------

| | 8.2 | Validation Reports
| | --- | ------------------

| | 8.3 | Master and Executed
Batch Records
| | --- | ---------------------------------

| | 8.4 | Master Labels
| | --- | -------------

| | 8.5 | Stability Reports
| | --- | -----------------

| | ****
shall be owned by Antares, and **** submission will be the responsibility of **** (subject
to the approval and authorization of Antares).
| | ----------------------------------------------------------------------------------------------------------------------------------------------

|9 | Project Management
|- | ------------------

| | 9.1. | **** will provide project management including project team meetings, summary
               status reports, conference calls, project coordination and on site visits.
| | ---- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

|10. | General Support
|--- | ---------------

| | 10.1. | **** will coordinate the preparation of Batch Records and they will be signed
               one (1) week prior to manufacturing; **** will coordinate the preparation of
               packaging and labeling protocols.
| | ----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 10.2. | **** will be responsible for report writing and issuance of the final report,
               and the final reports will be jointly approved by **** and ****.
| | ----- | -------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 10.3. | cGMP batch records will be prepared by **** and approved by ****.
| | ----- | -----------------------------------------------------------------

| | 10.4. | Method Validation or Transfer Protocols for the drug product will be prepared by
               **** and approved by ****, if required.
| | ----- | ---------------------------------------------------------------------------------------------------------------------------------------

| | 10.5. | **** Quality Assurance Department will audit and ensure cGMP compliance for the
               manufacturing of the ****.
| | ----- | -------------------------------------------------------------------------------------------------------------------------

| | 10.6. | Waste from the manufacturing process will be incinerated. Any unused excipients
               will be destroyed after expiry date, as it arises.
| | ----- | -------------------------------------------------------------------------------------------------------------------------------------------------

| | 10.7. | Dedicated excipients and packaging components will be destroyed six (6) months
               after completion of the manufacturing campaign. If **** elects for **** to store
               the materials longer than six (6) months then there will be a storage charge of
               $200 per month per ****.
| | ----- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 10.8. | Legal support required for execution of agreements will be provided by ****.
| | ----- | ----------------------------------------------------------------------------

| | 10.9. | **** will prepare necessary documentation for **** submission. However, the ****
               submission will be the responsibility of ****.
| | ----- | ----------------------------------------------------------------------------------------------------------------------------------------------

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

# Timing and Project
Initiation:

The project will commence upon
receipt of the signed contract, the drug substance, and the initiation payment, thereafter
payments are due thirty (30) days from the date of invoice.

Wire transfer information:

********ABA: ****A/C #: ****

Timing  Timing will be
finalized once the contract is signed but will be in line with **** needs.

Microsoft Project timeline will be
provided once contract is signed.

|Month 1: | Receive API, signed contract, initiation payment Initiate formulation development
activities Initiate cleaning method development Initiate analytical method development
Initiate technical transfer document
|-------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Months 2 / 3: | Develop discriminating dissolution method and perform dissolution testing of
innovator product Manufacture of prototypes Send development samples to **** for taste
masking evaluation and results to be provided to **** one (1) week after receipt of
samples Place prototypes on stability (**** set date is preferred) Develop drug product
methods
|------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Months 3 / 4 / 5: | Validate drug product methods
Manufacture
feasibility batches (week of **** is preferred) Prepare Master Batch Records Order tablet
and blister tooling (**** deadline preferred)
|----------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Month 5 / 6: | Manufacture **** (Week of **** is preferred)
Package ****Place
product on stability in one (1) package configuration
|------------ | --------------------------------------------------------------------------------------------------------------------

|Month 7 / 8 / 9: | Provide **** documentation to ****.
|---------------- | -----------------------------------

# (B)      Cost:

Stability is charged at **** for the
active per pull point including testing and storage. The stability activities and
associated costs are listed in the table below along with the additional cost

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

of testing
the 30(Degree)C/65% RH samples according to the stability protocol should **** at the
request of Antares elect to test such samples (optional cost).

|Stability Activity Cost Table                                                                                                                                                                                                                                            
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
|Monitor, test & store up to three (3) years per protocol:

1.   Six (6) month stability program                                                                                                                                                                          
|   
Packaged product stability program for two (2) active batches at the
following storage conditions:           25°C/60% RH at 3 and 6 months and
40°C/75% RH at 1, 2, and 3 months.         
(5) pull points x (2) active batches x (1) packaging configuration x ****
|Packaged product stability program for one (1) active batch at warehouse
conditions at 1, 3 and 6          months. (3) pull points x (2) active batches x
(1) packaging configuration x ****                                                                             
|                                                                                                                                                                                                                                                                         
|2.   Additional stability program beyond six (6) months                                                                                                                                                                                                                  
|   Packaged product stability program for two (2) active batches at the
following storage conditions:         25°C/60% RH at **** months.   (5)
pull points x (2) active batches x (1) packaging          configuration x ****                                          
|3.   Contingency stability cost for 30°C/65% RH storage condition                                                                                                                                                                                                        
|   Each condition charged at **** per pull point per active batch                                                                                                                                                                                                       
|Total Project Cost                                                                                                                                                                                                                                                       

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

Stability Study
Payment Schedule

|Invoice Issue
Date |                                                        | Amount Due for
**** | Invoice Date and
#
|------------------ | ------------------------------------------------------ | ------------------- | ------------------
|Stability Set      | Initiation Fee (non-refundable up to
three (3) months) | ****                |                   
|Month ****         | **** month pull point                                  | ****                |                   
|Month ****         | **** month pull point                                  | ****                |                   
|Month ****         | **** month pull point                                  | ****                |                   
|Month ****         | **** month pull point                                  | ****                |                   
|Month ****         | **** month pull point                                  | ****                |                   
|Month ****         | **** month pull point                                  | ****                |                   
|Total              |                                                        | ****                |                   

Stability Study Payment Schedule for Bulk Stability

|Invoice Issue
Date |                                                        | Amount Due | Invoice Date and
#
|------------------ | ------------------------------------------------------ | ---------- | ------------------
|Stability Set      | Initiation Fee (non-refundable up to
three (3) months) | ****       |                   
|Total              |                                                        | ****       |                   

NOTE: Release testing will be
considered time 0; however, if the product is not set within thirty (30) days of
manufacturing then the initial time point will be required. This cost is not included in
this table; therefore, **** will invoice Antares separately for the initial time point.

The Cost Table below lists the cost
of each step of the program. If **** and **** with the authorization of Antares mutually
agree in writing that additional man-hours are required for completion of a step, ****
shall invoice such additional man-hours to Antares provided however, such invoice
describes in detail the additional work conducted by ****.

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

|Activity for Orally Disintegrating Tablet  **** Strengths  **** Submission | ****                                                                                                                                                                                      
|---------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Section 1:                                                                   | Materials                                                                                                                                                                                 
|1.1                                                                          | API - full release testing will be charged - estimated **** / lot                                                                                                                         
|1.2                                                                          | Excipients - full release testing will be charged - estimated **** / lot; ****
will use stock excipients where applicable and may opt to charge on a per Kg basis.                        
|1.3                                                                          | Packaging Components - release testing will be charged - estimated **** / lot;
**** will use stock components where applicable and may opt to charge on a per
component basis.            
|Section 2:                                                                   | Formulation Development                                                                                                                                                                   
|2.1                                                                          | Comparative dissolution of innovator product - 3 lots x **** per lot x 2 strengths                                                                                                        
|2.2                                                                          | Manufacture of two (2) prototype batches including testing, **** for direct
compression to repeat current formulation process                                                             
|2.3                                                                          | Stability - 3 time points x **** x 1 strength x 2 package configurations                                                                                                                  
|Section 3:                                                                   | Manufacture of Feasibility Batches   two (2) batches (one of each strength) -
**** per batch for direct compression                                                                      
|Section 4:                                                                   | Manufacture of ****                                                                                                                                                                       
|4.6                                                                          | Manufacture of one (1) **** (****) and one (1) **** (****) of approximately ****
tablets each - total two (2) batches for **** submission.         (**** per batch
for direct compression)
|Section 5:                                                                   | Packaging and Labeling of ****                                                                                                                                                            
|5.3                                                                          | Packaging of one (1) **** into one (1) package configuration and one (1) **** into
one (1) package configuration for **** submission with a total of two (2) batches
- **** per batch.    
|5.4                                                                          |                                                                                                                                                                                           
|Section 6:                                                                   | Stability of ****                                                                                                                                                                         
|6.2                                                                          |                                                                                                                                                                                           
|6.2                                                                          | Stability of Packaged Product - 10 time points x **** x 2 strengths x 1 batch                                                                                                             
|6.3                                                                          | ****                                                                                                                                                                                      
|Section 7:                                                                   | Analytical Support                                                                                                                                                                        
|7.1                                                                          | Analytical Method Development and Validation                                                                                                                                              
|                                                                             |    Cleaning  method validation                                                                                                                                                          
|                                                                             |    Assay for drug product                                                                                                                                                                
|                                                                             |    Dissolution for drug product                                                                                                                                                          
|7.2                                                                          | Validation of API Methods                                                                                                                                                                 
|                                                                             |    Assay and Related Substances                                                                                                                                                          
|                                                                             |    Residual Solvents                                                                                                                                                                     
|7.3                                                                          | Innovator Testing                                                                                                                                                                         
|                                                                             |                                                                                                                                                                                           
|Section 8:                                                                   | **** Documentation                                                                                                                                                                        
|Section 9:                                                                   | Project Management                                                                                                                                                                        
|Section 10:                                                                  | General Support                                                                                                                                                                           
|Total                                                                        |                                                                                                                                                                                           

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

# Non-Stability Payment
Schedule

|Invoice Issue Date | Section
Reference | Activity                                                            | Amount Due for
**** | Invoice Date and #
|------------------ | ----------------- | ------------------------------------------------------------------- | ------------------- | ------------------
|****               | 8,9,10            | Initiation Payment                                                  | ****                |                   
|****               | 7                 | Cleaning method validation                                          | ****                |                   
|****               | 2                 | Completion of Innovator  Testing and Manufacture of  Two Prototypes | ****                |                   
|****               | 2                 | Stability Initiation of Prototypes (non refundable up  to 3 months) | ****                |                   
|****               | 3                 | Completion of feasibility  batches                                  | ****                |                   
|****               | 4                 | Master Batch Records                                                | ****                |                   
|****               | 4                 | Executed Batch Records                                              | ****                |                   
|****               | 5                 | Executed Packaging and Labeling Protocols                           | ****                |                   
|****               | 7                 | Method Validation Protocols for Drug Product                        | ****                |                   
|****               | 7                 | Method Validation Reports for  Drug Product                         | ****                |                   
|****               | 7                 | Method Validation Protocols  for API                                | ****                |                   
|****               | 7                 | Method Validation Reports for  API                                  | ****                |                   
|****               | 7                 | Innovator Testing                                                   | ****                |                   
|****               | 1                 | Materials & Testing                                                 | ****                |                   
|Total              |                   |                                                                     | ****                |                   

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.

---

In addition to the above costs,
Antares shall pay to **** upon receipt of **** invoice for all non-capital materials
(excipients, packaging components, HPLC columns, analytical standards, microbial testing
and tooling) used in the study at cost plus 10%. **** shall obtain Antares prior
written approval for any expenditure greater than ****. For high priced items more than
****, **** will charge cost plus 5% to Antares. **** shall invoice Antares for all
reasonable and normal out-of pocket travel related expenses, including airfare, room &
board, car rental and the like, of **** during any technology transfer phase or project
update meetings requested in advance by Antares and ****.

Shipments outside of Service Contract
work scope will be invoiced as per the following:

|a) | Shipment requests with three (3) days notice will be charged at **** plus
          shipping costs and a 10% service charge on shipping.
|-- | ----------------------------------------------------------------------------------------------------------------------------------------

|b) | Shipment requests with two (2) days notice will be charged at **** plus shipping
          costs and a 10% service charge on shipping.
|-- | --------------------------------------------------------------------------------------------------------------------------------------

|c) | Shipment requests with twenty-four (24) hours notice will be charged at ****
          plus shipping costs and a 10% service charge on shipping.
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------

****  Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed
separately with the Securities and Exchange Commission.